Investors' belief in Societal CDMO's lackluster revenue performance not improving may be causing its low P/S ratio. The company's inferior revenue outlook compared to the industry average contributes to this. A significant change in fortune is needed to justify a higher P/S.
The company's high debt and lack of profitability strain its balance sheet. Negative free cash flow adds risk, but its US$417.4m market cap could potentially allow capital raising to strengthen the balance sheet.
Investors' belief in Avid Bioservices' stagnant revenue performance and future growth lagging behind the industry has led to its low P/S. The underwhelming revenue outlook and shareholders' pessimism impact the P/S negatively.
Despite good revenue growth, the market expected more, as seen in the share price drop. This could hint at delayed revenue growth. The recent sell-off might be an investment chance considering the signs of a continued growth trend.
Avid Bioservices股票討論區
Most anticipated earnings and economic releases for the coming week, June 19th 23’
...
$醫療保健精選行業指數ETF-SPDR(XLV.US)$$Catalyst Pharmaceuticals(CPRX.US)$$Avid Bioservices(CDMO.US)$$Anixa Biosciences(ANIX.US)$$bluebird bio(BLUE.US)$
Current top watch ⚡️⚡️
2023上半年營收雖然還在增長,但利潤幾乎歸零,目前看起來估值並不低。
專欄Today's Pre-Market Stock Movers: NIO, PATH, COUP, RKLB and More
In reaction to earnings/guidance:
• $Coupa Software(COUP.US)$ +12% (also authorizes new $100mln share repurchase program),$REV Group(REVG.US)$ -5%,$G-III服裝集團(GIII.US)$ + 2.1%,$Gitlab(GTLB.US)$ +1.2%
Other news:
• $特百惠(TUP.US)$ +6.7% (recovers a bit after falling -33% during regular session)
• $Avaya Holdings(AVYA.US)$ +6.6% (authorizes workforce reduction plan)
• $巴西特家具(BSET.US)$ +5% (acqu...
暫無評論